Enzalutamide (ENZ) is used to treat patients with castration-resistant prostate cancer (CRPC). However, the kinetics of serum androgens before and after ENZ treatment are unknown.
To elucidate the kinetics of serum androgens and explore the possibility of identifying a useful marker for predicting the effects of ENZ.